Journal: American Journal of Cancer Research

Article Title: ERα is a target for butein-induced growth suppression in breast cancer

doi:

Figure Lengend Snippet: Butein enhances the anti-cancer effect of fulvestrant in ERα+ BCa. A. MCF-7 and T47D cells were exposed to butein (0, 2.5, 5, 10, 20 μM), fulvestrant (1 nM), or the combination of the both agents for 48 h in triple. 20 μl MTS were added to measure cell viability. *P<0.05, #P<0.01, &P<0.001 versus each vehicle control. B. T47D cells were exposed to butein, fulvestrant, or the both for 24 h. Colonic formation assay was performed. The showed images were from three independent experiments. C. MCF-7 and T47D cells were treated with butein, fulvestrant, or both for 24 h. Protein lysates were extracted for ERα and Cyclin D1 expression. D. Cells were treated with butein, fulvestrant, or both for 24 h. Edu stain assay were performed and images were captured using fluorescence microscope in triple. E. T47D cells were treated and collected, subjected to FACS for cell distribution. F. The percent of cell number was calculated.

Article Snippet: Butein (S8036, at a purity of 99%), MG132 (S2619, at a purity of 97%) and fulvestrant (S1191, at a purity of 99.86%) were purchased from Selleckchem (Houston, TX, USA).

Techniques: Control, Tube Formation Assay, Expressing, Staining, Fluorescence, Microscopy

Journal: Theranostics

Article Title: 3,4-Dimethoxychalcone, a caloric restriction mimetic, enhances TFEB-mediated autophagy and alleviates pyroptosis and necroptosis after spinal cord injury

doi: 10.7150/thno.78370

Figure Lengend Snippet: 3,4-DC activates TFEB through the AMPK-TRPML1-calcineurin signalling pathway. (A-D) WB analyses showing mTOR, p-mTOR, p70S6K, p-p70S6K, TRPML1, calcineurin, cytoplasmic and nuclear TFEB, caspase-1, GSDMD-N, p62, LC3, RIPK3, p-RIPK3, MLKL, and p-MLKL levels in the injured spinal cord of all groups on day 3 after SCI (the SCI, SCI+MHY1485, SCI+3,4-DC, and SCI+3,4-DC/MHY1485 groups); β-actin or histone H3 was utilized as the loading control. The densitometry quantification shown on the right reveals that MHY1485 (an mTOR agonist) inhibited the 3,4-DC-induced effects. (E) Schematic illustrating the proposed molecular mechanism by which 3,4-DC enhances autophagy after SCI by activating the AMPK-TRPML1-calcineurin signalling pathway, thereby promoting the nuclear translocation of TFEB. The induction of autophagy inhibits pyroptosis and necroptosis progression in the injured spinal cord. The data are presented as the means ± SEMs ( n = 6 mice per group); *P < 0.05, **P < 0.01, and ***P < 0.001 indicate significant differences. Significance was calculated using two-way ANOVA followed by Tukey's multiple comparison test.

Article Snippet: Compound C (C24H25N5O; purity ≥ 98.14%, cat# 866405-64-3), MHY1485 (C17H21N7O4; purity ≥ 99.86%, cat# HY-B0795), tacrolimus (C44H69NO12; purity ≥ 99.93%, cat# HY-13756), and gentamicin sulphate (C24H55N7O11S3; cat# HY-A0276) were purchased from Med Chem Express (Monmouth Junction, NJ, USA).

Techniques: Control, Translocation Assay, Comparison